In vivo anti-tumor activity of a new doxorubicin conjugate via α-linolenic acid

Bioscience, Biotechnology and Biochemistry

Volumn 76, Issue 8, 2012, Pages 1577-1579

  Huan, Menglei ^a   Cui, Han ^a   Teng, Zenghui ^a   Zhang, Bangle ^a   Wang, Jieping ^b   Liu, Xinyou ^b   Xia, Hui ^c   Zhou, Siyuan ^a   Mei, Qibing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

linolenic acid; Antitumor; Doxorubicin; Prodrug

Indexed keywords

ANTI-TUMOR ACTIVITIES; ANTI-TUMORS; CHEMOTHERAPY AGENTS; CLINICAL USE; DOXORUBICIN; DOXORUBICIN CONJUGATES; HEALTHY TISSUES; IN-VIVO; LINOLENIC ACIDS; PRODRUGS;

CHEMOTHERAPY; TOXICITY; TUMORS;

FATTY ACIDS;

ANTINEOPLASTIC AGENT; DOXORUBICIN; DRUG DERIVATIVE; LINOLENIC ACID;

ANIMAL; ARTICLE; BREAST TUMOR; CANCER TRANSPLANTATION; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ENDOCYTOSIS; FEMALE; HUMAN; IC 50; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; MOUSE; MOUSE MUTANT; PATHOLOGY; SURVIVAL RATE; SYNTHESIS; TUMOR CELL LINE; TUMOR VOLUME;

ALPHA-LINOLENIC ACID; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENDOCYTOSIS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; SURVIVAL RATE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865451613     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.120256     Document Type: Article

References (14)

1. Tan ML, Choong PF, and Dass CR, J. Pharm. Pharmacol., 61, 131-142 (2009).
2. Cheng D, Cao N, Chen J, Yu X, and Shuai X, Biomaterials, 33, 1170-1179 (2012).
3. Zeng X, Zhang H, Oh A, Zhang Y, and Yee D, Breast Cancer Res. Treat., 133, 117-126 (2012).
4. Chen CH, Cuong NV, Chen YT, So RC, Liau I, and Hsieh MF, J. Nanosci. Nanotechnol., 11, 53-60 (2011).
5. Tongu M, Harashima N, Yamada T, Harada T, and Harada M, Cancer Immunol. Immunother., 59, 769-777 (2010).
6. Arias JL, Mini Rev. Med. Chem., 11, 1-17 (2011).
7. Greish K, Methods Mol. Biol., 624, 25-37 (2010).
8. Horia E and Watkins BA, J. Nutr. Biochem., 16, 184-192 (2005).
9. Biondo PD, Brindley DN, Sawyer MB, and Field CJ, J. Nutr. Biochem., 19, 787-796 (2008).
10. Igarashi M and Miyazawa T, Lipids, 40, 109-113 (2005).
11. Huan M, Zhou S, Teng Z, Zhang B, Liu X, Wang J, and Mei Q, Bioorg. Med. Chem. Lett., 19, 2579-2584 (2009).
12. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, and Thomas TP, Cancer Res., 65, 5317-5324 (2005).
13. Qi L and Xu Z, Bioorg. Med. Chem. Lett., 16, 4243-4245 (2006).
14. Fauser JK, Prisciandaro LD, Cummins AG, and Howarth GS, Cancer Biol. Ther., 11, 724-731 (2011).